Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nab-TPC Versus GP Chemotherapy Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma: Randomized Controlled, Multi Center, Phase III Clinical Study

NCT06669611 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06669611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06669611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nab-TPC Versus GP Chemotherapy Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma: Randomized Controlled, Multi Center, Phase III Clinical Study
Lead sponsor
Sun Yat-sen University
Phase
Phase 3
Overall status
Recruiting
Start date
November 27, 2024
Completion date
November 20, 2029
Enrollment
242 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nasopharyngeal cancinoma (npc)